Cloud-Clone warns against fake multiplex assay kits

Cloud-Clone is drawing a sharp line between true multiplex biomarker platforms and ELISA plates assembled from separate single-analyte tests. The company says the difference matters for limited samples, data quality and throughput in immunology and disease research.

Why it matters: - Researchers working with small or irreplaceable samples can lose material fast if they use a product that looks multiplex but still requires separate wells for each analyte. - Cloud-Clone says patch-work ELISA panels can waste sample volume, weaken data comparability and delay studies that depend on reliable biomarker readouts.

What happened: - Cloud-Clone published a warning on Aug. 26, 2026, arguing that some products marketed as multiplex assay kits are actually physical assemblies of single-analyte ELISA tests. - The company said true multiplex detection should measure multiple targets from one sample in one reaction system. - Cloud-Clone contrasted those products with liquid-phase multiplex platforms used in biomarker research.

The details: - In partition-assembled ELISA, different capture antibodies are coated in separate rows or columns of one 96-well plate. - A single sample must be split across multiple wells, with the number of wells matching the number of analytes. - Cloud-Clone said that approach does not create a chemically integrated multiplex assay. - The company said mature liquid-phase multiplex systems use encoded microspheres to capture multiple targets in one well. - Cloud-Clone said those systems can use 25 microliters of sample to quantify more than a dozen analytes in one run. - The company said patch-work ELISA products require N-fold sample volume for N analytes, which is a problem for cerebrospinal fluid, mouse plasma and other limited specimens. - Cloud-Clone said assembled ELISA panels also lack joint cross-reaction validation under mixed-matrix conditions. - The company said that makes direct correlation or network analysis less reliable because reactions occur in separate wells under separate conditions. - Cloud-Clone said patch-work plates can show edge effects and well-to-well variation, lowering precision versus standalone single-analyte ELISA. - The company said the same products trail liquid-phase multiplex platforms on throughput because they require multiple wells and multiple reactions. - Cloud-Clone identified Luminex liquid-phase suspension microsphere assays, flow-based CBA and MSD electrochemiluminescence as the main mature multiplex technologies. - The company said Luminex supports 2 to 100 analytes per well with pg-level sensitivity. - Cloud-Clone said flow-based CBA works with standard flow cytometers. - The company said MSD offers fg/mL-level sensitivity, a 5-6 order-of-magnitude dynamic range and strong anti-matrix-interference capacity, but supports no more than 10 analytes per well and comes with higher instrument and reagent costs. - Cloud-Clone said its own multiplex kits use Luminex and flow-based CBA platforms. - The company said its portfolio includes more than 7,000 analytes covering more than 10 species. - Cloud-Clone said it also has self-produced antibody and protein raw materials, cross-reaction validation workflows and compatibility with common flow cytometers and dedicated Luminex analyzers. - The company directed researchers to more information.

Between the lines: - Cloud-Clone is making a market-positioning argument as much as a technical one. - The message is aimed at labs that may be comparing apparent price savings against the hidden cost of sample loss, repeat experiments and weaker datasets. - The strongest claim in the release is that physical plate assembly is not equivalent to a unified multiplex assay, even if the product is sold under that label.

What's next: - Cloud-Clone is steering researchers toward its own liquid-phase multiplex platforms and away from assembled ELISA panels. - The company said it is available for technical consultation on assay selection. - Researchers choosing among single-analyte ELISA, Luminex, flow-based CBA and MSD will likely weigh sample size, instrument access, analyte count and cost before buying.